AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8759264 — intervention group
Group type: COMPARATOR
Intervention: Normal saline drops (placebo)
Number of subjects: 12
Study 1930769 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrogen dioxide exposure at 0.05 ppm with peaks of 2.0 ppm for 15 minutes; bronchoalveolar lavage 3.5 hours after exposure
Number of subjects: 38
Study 1930769 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nitrogen dioxide exposure at 0.60 ppm; bronchoalveolar lavage 18 hours later
Number of subjects: 38
Study 1930769 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nitrogen dioxide exposure at 1.5 ppm; bronchoalveolar lavage 3.5 hours after exposure
Number of subjects: 38
Study 1930769 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbachol exposure (10 mg/mL) after nitrogen dioxide exposure
Number of subjects: 38
Study 1930769 — intervention group
Group type: COMPARATOR
Intervention: Carbachol exposure (10 mg/mL) after air exposure
Number of subjects: 38
Study 1930769 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage analysis during all three phases
Number of subjects: 38
Study 6627695 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide, 30 mg daily
Number of subjects: 5
Study 6627695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 30113395 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (NE) 6 µg
Number of subjects: 112
Study 30113395 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine (PE) 100 µg
Number of subjects: 112
Study 29764293 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological educational intervention
Number of subjects: 327
Study 29764293 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial educational intervention
Number of subjects: 327
Study 29764293 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 327
Study 27342831 — intervention group
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec (T-VEC)
Number of subjects: 436
Study 24666617 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (dAPT) - clopidogrel (75 mg) plus aspirin (300 mg)
Number of subjects: 219
Study 24666617 — intervention group
Group type: COMPARATOR
Intervention: Aspirin-monotherapy (300 mg)
Number of subjects: 219
Study 24666617 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (dAPT)
Number of subjects: 219
Study 20497186 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate
Number of subjects: 87
Study 20497186 — intervention group
Group type: COMPARATOR
Intervention: Control (no etidronate)
Number of subjects: 87
Study 19328650 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure bands with neutral information (Arm 2)
Number of subjects: 88
Study 19328650 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure bands with positive information (Arm 3)
Number of subjects: 88
Study 19328650 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Arm 1)
Number of subjects: 88
Study 19328650 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined acupressure bands (Arms 2 and 3)
Number of subjects: 88
Study 17379678 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger adults
Number of subjects: 24
Study 17379678 — intervention group
Group type: COMPARATOR
Intervention: Older adults
Number of subjects: 24
Study 15673224 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant simulator with New York State parenting curriculum
Number of subjects: 236
Study 15673224 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 236
Study 11230779 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone
Number of subjects: 29
Study 11230779 — intervention group
Group type: EXPERIMENTAL
Intervention: glibenclamide
Number of subjects: 29
Study 11230779 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 29
Study 9699192 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation intervention (health education sessions)
Number of subjects: 86
Study 9699192 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86
Study 9699192 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation intervention
Number of subjects: 86
Study 7908610 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucindolol 200 mg/d (high dose)
Number of subjects: 141
Study 7908610 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucindolol 12.5 mg/d (low dose)
Number of subjects: 141
Study 7908610 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucindolol 50 mg/d (medium dose)
Number of subjects: 141
Study 7908610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 3171039 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for isolated systolic hypertension
Number of subjects: 551
Study 3171039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 551
Study 28473401 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 35
Study 28473401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 26253332 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention of Delirium Programme
Number of subjects: 16
Study 26253332 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 16
Study 24409029 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive activity combined with physical exercise (CAE), n=11
Number of subjects: 30
Study 24409029 — intervention group
Group type: COMPARATOR
Intervention: Only cognitive activity (CA), n=9
Number of subjects: 30
Study 21907780 — intervention group
Group type: EXPERIMENTAL
Intervention: ModraDoc001 15 mg capsules
Number of subjects: 0
Study 21907780 — intervention group
Group type: COMPARATOR
Intervention: docetaxel premix solution (TAXOTERE)
Number of subjects: 0
Study 19595438 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrathiomolybdate
Number of subjects: 143
Study 19595438 — intervention group
Group type: COMPARATOR
Intervention: Trientine
Number of subjects: 143
Study 17032704 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention with parental involvement
Number of subjects: 15
Study 17032704 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention alone
Number of subjects: 15
Study 17032704 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study 12642306 — intervention group
Group type: EXPERIMENTAL
Intervention: Single lyophilisate (204 mg)
Number of subjects: 22
Study 12642306 — intervention group
Group type: COMPARATOR
Intervention: Three conventional eye drops (40 ml fluorescein SE Thilo 0.17%)
Number of subjects: 22
Study 10673700 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg LSF
Number of subjects: 60
Study 10673700 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg LSF
Number of subjects: 60
Study 10673700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9266139 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies to block TNF-alpha
Number of subjects: 0
Study 9266139 — intervention group
Group type: COMPARATOR
Intervention: IL-1 receptor antagonist
Number of subjects: 0
Study 9266139 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapies with monoclonal antibodies and long-acting rheumatic drugs (e.g., methotrexate)
Number of subjects: 0
Study 8184764 — intervention group
Group type: EXPERIMENTAL
Intervention: Biplane left ventriculography at 3 weeks and 1 year after myocardial infarction
Number of subjects: 52
Study 8184764 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients selected for late ventricular enlargement (change in ED volume > 20 ml, n = 19)
Number of subjects: 52
Study 3513801 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin, 25 mg, four times a day during therapy
Number of subjects: 19
Study 3513801 — intervention group
Group type: COMPARATOR
Intervention: Placebo, four times a day during therapy
Number of subjects: 19
Study 30088841 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic preparation containing Lactobacillus, Bifidobacterium, and Streptococcus spp., 2 capsules daily for 14 days
Number of subjects: 100
Study 30088841 — intervention group
Group type: COMPARATOR
Intervention: Placebo, daily for 14 days
Number of subjects: 100
Study 29342390 — intervention group
Group type: EXPERIMENTAL
Intervention: Household-contact investigation plus standard passive case finding
Number of subjects: 25707
Study 29342390 — intervention group
Group type: COMPARATOR
Intervention: Passive case finding alone
Number of subjects: 25707
Study 25802980 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA (eicosapentaenoic acid) 1060 mg day(‐1)
Number of subjects: 155
Study 25802980 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (docosahexaenoic acid) 900 mg day(‐1)
Number of subjects: 155
Study 25802980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 25802980 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA (eicosapentaenoic acid)
Number of subjects: 155
Study 24670088 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg)
Number of subjects: 12
Study 22738908 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery Rehearsal Therapy
Number of subjects: 69
Study 22738908 — intervention group
Group type: COMPARATOR
Intervention: Control condition (for PTSD patients)
Number of subjects: 69
Study 19404656 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 140
Study 19404656 — intervention group
Group type: EXPERIMENTAL
Intervention: Transobturator tape (TOT)
Number of subjects: 140
Study 17137468 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Treatment
Number of subjects: 165
Study 17137468 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 165
Study 15147016 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis (CAD) system using characteristic-point-based fuzzy inference system (CPFIS)
Number of subjects: 109
Study 15147016 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal images)
Number of subjects: 109
Study 12070645 — intervention group
Group type: EXPERIMENTAL
Intervention: ACD anticoagulant (group A)
Number of subjects: 81
Study 12070645 — intervention group
Group type: COMPARATOR
Intervention: No additives (group B)
Number of subjects: 81
Study 9805326 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Alzheimer's disease (AD) patients
Number of subjects: 0
Study 9805326 — intervention group
Group type: EXPERIMENTAL
Intervention: Early vascular dementia (VaD) patients
Number of subjects: 0
Study 9805326 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study 9805326 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall naming errors
Number of subjects: 0
Study 9805326 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic errors
Number of subjects: 0
Study 7705801 — intervention group
Group type: COMPARATOR
Intervention: L‐alanyl‐L‐tyrosine (Ala‐Tyr)
Number of subjects: 13
Study 7705801 — intervention group
Group type: COMPARATOR
Intervention: glycyl‐L‐tyrosine (Gly‐Tyr)
Number of subjects: 13
Study 7705801 — intervention group
Group type: COMPARATOR
Intervention: N‐acetyl‐L‐tyrosine (Nac‐Tyr)
Number of subjects: 13
Study 2198140 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1
Number of subjects: 37
Study 2198140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 356598 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimazosin
Number of subjects: 22
Study 356598 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 22
Study 356598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 30328153 — intervention group
Group type: EXPERIMENTAL
Intervention: High-vitamin level diet (DSM vitamin regimen)
Number of subjects: 432
Study 30328153 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-vitamin level diet (50% low-vitamin level diet and 50% high-vitamin level diet)
Number of subjects: 432
Study 30328153 — intervention group
Group type: COMPARATOR
Intervention: Low-vitamin level diet (70% NRC vitamin regimen)
Number of subjects: 432
Study 28478214 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% carbamide peroxide gel in tray
Number of subjects: 26
Study 28478214 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5% hydrogen peroxide strip
Number of subjects: 26
Study 28478214 — intervention group
Group type: COMPARATOR
Intervention: Comparison between tray and strip groups
Number of subjects: 26
Study 25196742 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable bed bath
Number of subjects: 58
Study 25196742 — intervention group
Group type: COMPARATOR
Intervention: Traditional basin bed bath
Number of subjects: 58
Study 23351409 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mL low-calorie cranberry juice cocktail (CJC) per day for 4 weeks
Number of subjects: 35
Study 23351409 — intervention group
Group type: COMPARATOR
Intervention: 500 mL placebo juice (PJ) per day for 4 weeks
Number of subjects: 35
Study 22093840 — intervention group
Group type: EXPERIMENTAL
Intervention: eFATE
Number of subjects: 83
Study 22093840 — intervention group
Group type: COMPARATOR
Intervention: Routine methods
Number of subjects: 83
Study 19672253 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 104
Study 19672253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 19672253 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (infliximab-experienced subgroup)
Number of subjects: 104
Study 19672253 — intervention group
Group type: COMPARATOR
Intervention: Placebo (infliximab-experienced subgroup)
Number of subjects: 104
Study 17453399 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (25 mg daily)
Number of subjects: 100
Study 17453399 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (100 mg daily)
Number of subjects: 100
Study 15794388 — intervention group
Group type: EXPERIMENTAL
Intervention: LA 600 mg twice a day
Number of subjects: 37
Study 15794388 — intervention group
Group type: EXPERIMENTAL
Intervention: LA 1200 mg once a day
Number of subjects: 37
Study 15794388 — intervention group
Group type: EXPERIMENTAL
Intervention: LA 1200 mg twice a day
Number of subjects: 37
Study 15794388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 15794388 — intervention group
Group type: EXPERIMENTAL
Intervention: LA (all doses)
Number of subjects: 37
Study 12207826 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of diagnostic and therapeutic algorithms in 11 nursing homes
Number of subjects: 22
Study 12207826 — intervention group
Group type: COMPARATOR
Intervention: Usual practice in 11 nursing homes
Number of subjects: 22
Study 12207826 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of diagnostic and therapeutic algorithms
Number of subjects: 22
Study 10713866 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of Lem1 (natural compound from lemon oil)
Number of subjects: 0
Study 8547043 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment (pulsed tunable dye laser)
Number of subjects: 8
Study 1919822 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (IVIG)
Number of subjects: 30
Study 1919822 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 30
Study 6255982 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of ACTH
Number of subjects: 20
Study 6255982 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 20
Study 31994186 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics
Number of subjects: 6986
Study 31994186 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated adolescent data
Number of subjects: 6986
Study 31575006 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy applied in the pre‐ and postoperative periods (Group 1)
Number of subjects: 90
Study 31575006 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy applied only in the postoperative period (Group 2)
Number of subjects: 90
Study 31575006 — intervention group
Group type: COMPARATOR
Intervention: Cold pack (gel ice) applied postoperatively (Group 3)
Number of subjects: 90
Study 29232436 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC plus a bioengineered ECM with living fibroblasts
Number of subjects: 0
Study 29232436 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC plus a bioengineered ECM devoid of cells
Number of subjects: 0
Study 29232436 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 0
Study 25982014 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI group (n = 175)
Number of subjects: 275
Study 25982014 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 88)
Number of subjects: 275
Study 23732957 — intervention group
Group type: EXPERIMENTAL
Intervention: Small group sexual and substance use risk reduction intervention based on empowerment theory
Number of subjects: 515
Study 23732957 — intervention group
Group type: COMPARATOR
Intervention: Enhanced efficacious control condition
Number of subjects: 515
Study 21241793 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Conscientiousness
Number of subjects: 200
Study 21241793 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Openness
Number of subjects: 200
Study 21241793 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal striving (subcomponent of Conscientiousness)
Number of subjects: 200
Study 21241793 — intervention group
Group type: EXPERIMENTAL
Intervention: Aesthetic interests (subcomponent of Openness)
Number of subjects: 200
Study 21241793 — intervention group
Group type: EXPERIMENTAL
Intervention: Common health behaviors and chronic illness
Number of subjects: 200
Study 19179549 — intervention group
Group type: COMPARATOR
Intervention: LV5FU2 alone
Number of subjects: 400
Study 19179549 — intervention group
Group type: EXPERIMENTAL
Intervention: LV5FU2 + IRI (irinotecan)
Number of subjects: 400
Study 17520860 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 g x kg(‐1) NaHCO3
Number of subjects: 8
Study 17520860 — intervention group
Group type: COMPARATOR
Intervention: 8 g NaCl (placebo)
Number of subjects: 8
Study 15363816 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan (600 mg/day)
Number of subjects: 30
Study 11603173 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg/day)
Number of subjects: 31
Study 11603173 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (400 mg/day)
Number of subjects: 31
Study 11603173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 9855227 — intervention group
Group type: EXPERIMENTAL
Intervention: No drain
Number of subjects: 90
Study 9855227 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotransfusion system
Number of subjects: 90
Study 9855227 — intervention group
Group type: COMPARATOR
Intervention: Standard disposable closed suction drainage system
Number of subjects: 90
Study 7521498 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin 7 mg/kg until the end of perfusion
Number of subjects: 30
Study 7521498 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline infusion)
Number of subjects: 30
Study 2631971 — intervention group
Group type: EXPERIMENTAL
Intervention: Biobehavioral treatment (bed rest, compliance enhancement training, and individualized thermal biofeedback-assisted relaxation training)
Number of subjects: 45
Study 2631971 — intervention group
Group type: COMPARATOR
Intervention: Bed rest with individualized compliance enhancement training
Number of subjects: 45
Study 2631971 — intervention group
Group type: COMPARATOR
Intervention: Bed rest alone
Number of subjects: 45
Study 70924 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.1 mg potassium dichromate
Number of subjects: 31
Study 70924 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 31
Study 70924 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 31
Study 31092077 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential embryo transfer on day 3 and day 5
Number of subjects: 120
Study 31092077 — intervention group
Group type: COMPARATOR
Intervention: Blastocyst embryo transfer on day 5
Number of subjects: 120
Study 28761608 — intervention group
Group type: EXPERIMENTAL
Intervention: Good knowledge level towards obstetric causes of maternal mortality
Number of subjects: 844
Study 28761608 — intervention group
Group type: EXPERIMENTAL
Intervention: Being a government employee
Number of subjects: 844
Study 28761608 — intervention group
Group type: EXPERIMENTAL
Intervention: Having additional monthly income from family members
Number of subjects: 844
Study 28761608 — intervention group
Group type: EXPERIMENTAL
Intervention: Attending primary school and above
Number of subjects: 844
Study 28761608 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance to health facility less than 20 minutes
Number of subjects: 844
Study 28761608 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance to health facility 20-39 minutes
Number of subjects: 844
Study 28761608 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance to health facility 40-60 minutes
Number of subjects: 844
Study 28761608 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous history of prolonged labor
Number of subjects: 844
Study 25832689 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Partial Breast Irradiation (APBI)
Number of subjects: 1108
Study 25832689 — intervention group
Group type: COMPARATOR
Intervention: Whole-breast irradiation
Number of subjects: 1108
Study 25832689 — intervention group
Group type: EXPERIMENTAL
Intervention: V95/whole-breast volume ratio <0.15
Number of subjects: 1108
Study 25832689 — intervention group
Group type: EXPERIMENTAL
Intervention: V95/whole-breast volume ratio
Number of subjects: 1108
Study 23871473 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (300 mg)
Number of subjects: 80
Study 23871473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 21493266 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel
Number of subjects: 31
Study 21493266 — intervention group
Group type: COMPARATOR
Intervention: Traditional technique (electrocautery and sharp dissection)
Number of subjects: 31
Study 19549427 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine/Montelukast (10 mg/10 mg once-daily)
Number of subjects: 1095
Study 19549427 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine (240 mg once-daily)
Number of subjects: 1095